Last reviewed · How we verify
RAYOS
RAYOS is a delayed-release formulation of prednisone that releases the corticosteroid in the colon to provide anti-inflammatory effects with reduced morning cortisol suppression.
RAYOS is a delayed-release formulation of prednisone that releases the corticosteroid in the colon to provide anti-inflammatory effects with reduced morning cortisol suppression. Used for Rheumatoid arthritis, Polyarticular course juvenile idiopathic arthritis, Psoriatic arthritis.
At a glance
| Generic name | RAYOS |
|---|---|
| Sponsor | Ampel BioSolutions, LLC |
| Drug class | Corticosteroid (delayed-release formulation) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
RAYOS uses a chronotherapeutic delivery system designed to release prednisone in the colon several hours after ingestion, typically in the early morning hours. This delayed-release approach aims to align drug delivery with the body's natural circadian rhythm of inflammation and cortisol production, potentially reducing systemic corticosteroid exposure and side effects compared to immediate-release prednisone while maintaining therapeutic efficacy.
Approved indications
- Rheumatoid arthritis
- Polyarticular course juvenile idiopathic arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Systemic lupus erythematosus
Common side effects
- Insomnia
- Headache
- Hypertension
- Hyperglycemia
- Mood changes
- Gastrointestinal upset
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement (NA)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |